## <sup>1</sup>**Multidrug-resistant organism bloodstream infections in solid organ transplant recipients and**

- <sup>2</sup>**impact on mortality: a systematic review**
- 
- 4 Alice Liu<sup>1</sup>, Adelaide Dennis<sup>1</sup>, Zarin Fariha<sup>1</sup>, Rekha Pai Mangalore<sup>1</sup>, Nenad Macesic\*<sup>1,2,3</sup>
- 5

## <sup>6</sup>**Affiliations**

- <sup>1</sup> Department of Infectious Diseases, The Alfred Hospital and School of Translational Medicine,
- 8 Monash University, Melbourne, Australia
- 9 <sup>2</sup> Centre to Impact AMR, Monash University, Clayton, Australia
- 10  $^{-3}$  Infection Prevention & Healthcare Epidemiology, Alfred Health, Melbourne, Australia.
- 11
- 12 \* Corresponding Author
- 13 Dr. Nenad Macesic, Department of Infectious Diseases, The Alfred Hospital and School of
- <sup>14</sup>Translational Medicine, Monash University, Level 1 Alfred Lane House, Alfred Hospital, 55
- <sup>15</sup>Commercial Rd, Melbourne, VIC 3004, Australia. Email: nenad.macesic1@monash.edu
- 
- <sup>17</sup>**Word count (excluding abstract): 2465**

### **Abstract (280 words)**

- *Background:* Bloodstream infections (BSI) cause significant morbidity and mortality in solid organ
- 20 transplant (SOT) recipients. There are few data regarding the contribution of multidrug-resistant
- 21 organisms (MDROs) to these infections.
- *Objectives:* We evaluated the resistance-percentage of MDRO BSIs in SOT recipients and
- 23 assessed associated mortality.
- *Methods:* A systematic review
- *Data sources:* MEDLINE and Embase databases up to January 2024.
- *Study eligibility criteria:* Studies of adult SOT recipients that quantify MDRO BSI resistance-
- 27 percentage and/or associated crude mortality. MDROs studied were carbapenem-resistant
- Enterobacterales (CRE), *Acinetobacter baumannii* (CRAB) and *Pseudomonas aeruginosa* (CRPA),
- 29 third-generation-cephalosporin-resistant Enterobacterales (3GCR-E), methicillin-resistant
- *Staphylococcus aureus* (MRSA) and vancomycin-resistant *Enterococcus faecium* (VRE).
- *Participants:* Adult SOT recipients with a microbiologically confirmed BSI.
- *Interventions:* Not applicable.
- *Risk of bias assessment:* Newcastle Ottawa Scale.
- *Methods of data synthesis:* MDRO BSI resistance-percentage and mortality outcomes were
- 35 reported as median (IQR) and crude mortality (%), respectively.
- *Results:* Of 945 studies identified, 52 were included. Most were retrospective (41/52) and/or single
- centre (37/52), and liver transplantation was the most studied SOT type (22/52). High resistance-
- 38 percentages of BSIs were noted, ranging from 13.6% CRE for Enterobacterales to 59.2% CRAB for
- *Acinetobacter baumannii*. Resistance-percentage trends decreased over time, but these changes
- were not statistically significant. Asia had highest resistance-percentages for MRSA (86.2% [IQR
- 77.3-94.6%]), 3GCR-E (59.5% [IQR 40.5-66.7%]) and CRE (35.7% [IQR 8.3-63.1%]). North America
- 42 had highest VRE resistance-percentages (77.7% [IQR 54.6-94.7%]). Crude mortality was 15.4-
- 43 82.4% and was consistently higher than non-MDRO BSIs.
- *Conclusions:* MDRO BSIs resistance-percentages were high for all pathogens studied (IQR 24.6-
- 69.4%) but there was geographical and temporal heterogeneity. MDRO BSIs were associated with

- 46 high mortality in SOT recipients. Microbiological and clinical data in this vulnerable population were
- 47 incomplete, highlighting the need for robust international multi-centre studies.

48

### <sup>49</sup>**Introduction**

50 Solid organ transplantation (SOT) provides a life-saving measure for patients with end-stage organ 51 failure. However, SOT recipients are at increased susceptibility to infection, which may result in 52 impaired graft function and adverse outcomes (1). Bloodstream infections (BSI) are a leading cause 53 of morbidity and mortality in this population (2-5), with mortality reaching 50% when associated with 54 septic shock (5, 6). Post-transplant BSIs result in prolonged hospital stays, need for re-admission 55 and substantial financial costs (4). Infections with multidrug-resistant organisms (MDROs) are 56 common among SOT recipients due to extended exposure to broad spectrum antimicrobials, 57 immunosuppressive medications, presence of chronic indwelling devices and frequent healthcare 58 exposure (7, 8). SOT itself has been described as an independent risk factor for certain MDRO 59 infections (8). MDRO infections are associated with greater mortality and increased risk of graft 60 failure than those caused by susceptible pathogens (7, 9, 10), posing a major challenge to individual 61 patient care. Furthermore, antimicrobial treatment options for these organisms are often limited and 62 may come with significant toxicities and cost. 63 <sup>64</sup>While there are multiple reports of high resistance rates and poor outcomes of BSIs in SOT 65 recipients (7, 11-13), there remains an urgent need to better understand the epidemiology and 66 temporal trends in these infections. In the absence of prior systematic review data, we provide a 67 comprehensive description of MDRO BSI resistance-percentages and associated mortality in SOT

<sup>68</sup>recipients, focusing on clinically relevant pathogens that influence empirical and directed

<sup>69</sup>antimicrobial decision making. The MDROs studied in this review represent a critical group of

70 pathogens that pose a significant global public health threat and are common causes of life-

71 threatening hospital-acquired infection (14).

<sup>73</sup>**Methods** 

74 Study selection

<sup>75</sup>We performed a systematic review of all published literature describing resistance-percentage <sup>76</sup>and/or mortality of BSIs due to MDROs among adult SOT recipients. Six MDROs were selected



### 105 Data extraction and analysis

106 Title and abstract screening were performed by AL. Full text screening was performed by three 107 reviewers (AL, AD, ZF), who also extracted data independently. Conflicts between reviewers on 108 eligibility assessments and data extraction results were resolved through discussion and consensus 109 among all authors. Duplicate studies were removed via Covidence systematic review software <sup>110</sup>(Veritas Health Innovation, Melbourne, Australia) and manual checking. Data were extracted using a 111 custom extraction template covering the following variables: study design, year and location, study 112 population size, type/s of transplant, MDRO species and their frequency, associated crude mortality <sup>113</sup>(where available) and antimicrobial susceptibility testing methods. Statistical analyses and 114 visualisations were performed with R v4.3.0 (2023). Specifically, we applied a linear regression 115 analysis using the 'lm' function to assess the presence of a trend in MDRO resistance-percentages 116 over time. 118 Risk of bias assessment 119 Quality assessment was conducted using the Newcastle Ottawa Scale (NOS) (17). For the NOS 120 assessment, exposure was defined as BSI due to MDRO. Comparability of cohorts was based on 121 controlling for baseline patient demographics and immunosuppression regimen. Assessment of <sup>122</sup>MDRO proportions was through microbiological confirmation with a description of the antimicrobial

123 susceptibility methods included. Assessment of mortality outcomes was through an independent

124 assessment or record linkage. There was no minimum follow-up period, and the shortest study 125 period was 12 months (18). Studies with a NOS score of 7 or greater were included in the final

126 analysis.

### <sup>128</sup>**Results**

### 129 Study characteristics

130 A total of 1137 studies were identified. After removal of duplicates, 945 were screened, of which 114 131 studies were retrieved and 52 included in the final analysis (Fig. 1). Reasons for exclusion (62 132 studies) were incorrect study design, outcomes not specific to BSIs or insufficient data on 133 antimicrobial susceptibility. Most studies were retrospective (41/52, 78.8%) and single-centre (37/52, 134 71.2%). Of the studies focused on a single transplant type, liver transplant was the most studied <sup>135</sup>(22/52, 42.3%), followed by kidney transplant (5/52, 9.6%). Eighteen (34.6%) studies included 136 pooled multiple transplant types in their analysis. Study population size was variable, ranging from <sup>137</sup>14 BSI episodes over a 3-year period (19) to 988 episodes over 10 years (8). Full details on the 138 characteristics of the included studies are provided in Supp. Table 3. Quality assessment using the 139 NOS is described in Supp. Tables 4 and 5.

### 141 Pooled estimates of MDRO BSIs in SOT recipients

142 Proportion of BSIs due to MDROs was reported in 49/52 studies with only crude mortality reported

143 in the remaining three studies. MDRO BSI resistance-percentages are shown in Table 1 and Fig. 2A

144 and ranged from 13.6% (IQR 8.7-37.0%) carbapenem resistance in Enterobacterales to 59.2% (IQR

145 50.0-77.4%) carbapenem resistance in *Acinetobacter baumannii*. We analysed MDRO resistance-

146 percentages over time and noted reducing trends for all MDROs except CRAB, but these changes

147 were not statistically significant (Table 1, Fig. 2B and Supp. Table 6).

148

<sup>149</sup>MDRO BSI resistance-percentage varied by region (Table 1), with Asia having highest median

150 resistance-percentages of MRSA (86% [IQR 77-95%]), 3GCR-E (60% [IQR 40-67%]), CRE (36%

151 [IQR 8-63%]) and CRAB (60% [IQR 54-89%]). North America had highest VRE resistance-

152 percentages (median 78% [IQR 55-95%]). South America had highest CRPA resistance-percentage

153 (88%), but this was based on results of a single study.

154



## <sup>177</sup>**Discussion**

178 Our systematic review aimed to quantify the burden of MDRO BSIs in SOT recipients and 179 successfully consolidated global antimicrobial resistance (AMR) data for multiple clinically relevant 180 pathogens that cause BSIs in SOT recipients. We observed high resistance-percentages for BSIs in 181 SOT recipients, ranging from median 13.6% for CRE BSIs to median 56.2% for CRAB BSIs.

182 However, there was considerable heterogeneity in resistance-percentages across different regions 183 and time periods. While there were decreasing trends in MDRO BSIs over time, CRAB remained an 184 exception. MDRO BSIs were associated with high crude mortality in SOT recipients, ranging from 185 15% up to 82.4% in one study in an intensive care setting (21).

<sup>187</sup>We noted prominent differences in MDRO BSI burden across regions. A key question arises 188 regarding comparison with AMR burden in the general population. Asia had highest resistance-189 percentages for multiple pathogens (MRSA, 3GCR-E, CRE and CRAB). These were higher than in 190 the general hospitalised population in Asia (30.5-49.0% for MRSA BSIs, 36.0-57.2% for 3GCR-E 191 BSIs and 23.1-26.1% for CRE BSIs) (23, 24) but lower for CRAB BSIs (median 60% in SOT 192 recipients vs. 71.5-90.5%) (23, 24). Most Asian studies were confined to liver transplant, which is 193 more commonly associated with post-operative bacterial infections (25-27). This, combined with 194 high overall rates of AMR in many Asian countries may explain the high resistance-percentages for 195 BSIs in SOT recipients we observed in this region (23, 28, 29). North America exhibited the highest 196 resistance percentage of VRE (median 76.6%), aligning with surveillance data demonstrating >70% 197 of US hospital *Enterococcus faecium* isolates are VRE (30). Conversely, Europe had the lowest 198 VRE resistance-percentages (median 3.0%). European general VRE surveillance data range widely 199 from <1% in Holland to 45% in Greece (31). In our review, Spanish (4/16, 25%) and Italian studies <sup>200</sup>(4/16, 25%) were most frequently represented, and our VRE findings reflected surveillance data 201 rates from both countries (3% and 11%, respectively) (31).

202

203 Resistance-percentages decreased over time for several of the pathogens studied (MRSA, VRE, <sup>204</sup>3GCR-E, CRE and CRPA). While these trends did not reach statistical significance, this finding 205 contrasts to global observations of increasing MDRO prevalence over time (32-35). MRSA is unique 206 in demonstrating an early rise and subsequent fall in its prevalence across multiple geographic 207 regions over the last two decades (36), potentially explaining our findings of reducing MRSA trends. 208 The decreasing prevalence of other MDROs over time may potentially be attributed to 209 improvements in infection control measures, better detection of donor-derived infections and

210 changes in antibiotic prophylaxis prescribing practices over time (37, 38). Furthermore, global AMR 211 surveillance methods are not standardised nor is coverage universal (39), and the resistance-212 percentage rates noted in this study represent specialised transplant centres rather than all 213 healthcare facilities. In contrast, we noted increasing CRAB resistance-percentages in our study, 214 which may reflect the contribution of frequent intensive care unit admission following SOT, with 215 healthcare-associated horizontal transmission of CRAB well described in this setting (40, 41). ---<br>-<sup>217</sup>We found high crude mortality rates among patients with MDRO BSIs ranging from 15.4 to 82.4%. 218 However, this was based on limited data (17 studies), with almost all studies reporting on <100 SOT 219 recipients with MDRO BSI. These findings contrast with prior reports that noted lower mortality in 220 SOT recipients with sepsis in the early post-transplant period than in non-SOT patients (42, 43). 221 However, these studies did not distinguish between BSI with susceptible and drug-resistant 222 pathogens. Even fewer studies ( $n=4$ ) compared mortality between MDRO and non-MDRO BSIs in 223 SOT recipients, but in these studies MDRO BSIs were consistently associated with a higher crude 224 mortality rate (10, 20, 44, 45). This may reflect use of empiric antibiotics with inadequate spectra of 225 activity. Alterations in the pathophysiology of different SOT recipients may also account for the high 226 overall mortality rate in this population. For example, heart transplant recipients have higher risk of 227 cardiogenic shock complicating septic shock, while lung transplant recipients are at greater risk of 228 respiratory failure requiring intubation and intensive care support (46).

229

230 Our study has several limitations. Firstly, the included studies were heterogeneous in their 231 population size and follow-up period. It was therefore not feasible to conduct a meta-analysis of the 232 study outcomes. The transplant type strongly influences the primary site of infection and associated 233 sepsis (47). We were unable to stratify MDRO frequency-percentages by transplant type because 234 many studies pooled multiple transplant types in their analyses. Additionally, data on prescribing 235 practices were inconsistently recorded across studies and there is a high likelihood that there were 236 geographical and temporal differences in therapeutic and prophylactic antimicrobial prescribing and 237 immunosuppression regimens. These differences would influence MDRO BSI frequency-

238 percentages observed. Finally, mortality data were not reported in a standardised manner, varying 239 from 5-day to 1-year mortality figures, limiting pooled analysis and comparison between studies.

241 Our review underscores several priorities in the care of SOT recipients. Our findings of high 242 resistance-percentages for BSIs and significant associated mortality highlight that prevention of <sup>243</sup>MDRO acquisition remains paramount. This includes but is not limited to proactive antimicrobial 244 stewardship pre- and post-transplantation to reduce selection pressure, infection control measures 245 to limit cross-transmission in hospital settings, and regular review of immunosuppressant 246 medications and indwelling devices to reduce the risk of colonisation. Strategies for early 247 identification of BSIs caused by MDROs may also help in timely antibiotic rationalisation and limiting 248 the emergence of MDROs in the transplant population, such as continued development of rapid 249 laboratory diagnostics and antimicrobial susceptibility testing methods, and implementation of 250 protocolised surveillance testing programs for donors and recipients.

251

<sup>252</sup>We also identified future research priorities. Our review found a paucity of transplant type-specific 253 microbiological data, non-standardised mortality reporting methods and a reliance on retrospective 254 and/or single centre data resulting in wide variation in study size. It has been noted that frequency 255 measures such as resistance-percentages are of limited use without accompanying population 256 resistance-percentage estimates or incidence-density data (48), which was also evident in our 257 review. Future work should focus on longitudinal prospective data collection using consistent 258 metrics, capturing both clinical and microbiological outcomes and representing SOT types 259 proportionately. This presents an opportunity to further develop and implement larger scale 260 transplant registries such as the Swiss Transplant Cohort study (11, 13) which capture infectious 261 complications and corresponding microbiological data.

### <sup>263</sup>**Conclusion**

264 Our findings reinforce that SOT recipients are highly vulnerable to MDRO BSIs and experience 265 substantial associated mortality. We identified marked geographical variation in the proportion of

- <sup>266</sup>MDRO BSIs, which warrants ongoing characterisation in future studies. While there was a trend
- 267 towards reducing resistance-percentages of several MDROs, this was not statistically significant
- 268 and certain pathogens were under-represented. We noted gaps in the reporting of transplant type-
- 269 specific data and a paucity of standardised mortality outcomes. Our study highlights the urgent need
- 270 for robust international multi-centre cohort studies that adequately capture microbiological data and
- 271 BSI clinical outcomes to guide prevention and empirical treatment strategies in this highly
- 272 vulnerable patient group.
- 273
- <sup>274</sup>**Transparency declarations**
- 275 None to declare
- 
- <sup>277</sup>**Funding**
- 278 This work was supported by the National Health and Medical Research Council of Australia
- 279 (Emerging Leader 1 Fellowship APP1176324 to N.M.).
- 280 The funders had no role in study design, data collection and interpretation, or the decision to submit
- 281 the work for publication.
- 

# <sup>283</sup>**References**

284 1. Fishman JA. Infection in solid-organ transplant recipients. N Engl J Med. 2007;357(25):2601-<br>285 14. <sup>285</sup>14.

286 2. Adelman MW, Connor AA, Hsu E, Saharia A, Mobley CM, Victor DW, 3rd, et al. Bloodstream<br>287 infections after solid organ transplantation: clinical epidemiology and antimicrobial resistance (2016-<sup>287</sup>infections after solid organ transplantation: clinical epidemiology and antimicrobial resistance (2016- 288 21). JAC Antimicrob Resist. 2024;6(1):dlad158.<br>289 3. Gavalda J. Aquado JM. Manuel O. Gros

289 3. Gavalda J, Aguado JM, Manuel O, Grossi P, Hirsch HH, Hosts ESGoliC. A special issue on<br>290 infections in solid organ transplant recipients. Clin Microbiol Infect. 2014:20 Suppl 7:1-3. 290 infections in solid organ transplant recipients. Clin Microbiol Infect. 2014;20 Suppl 7:1-3.<br>291 4. Kritikos A, Manuel O. Bloodstream infections after solid-organ transplantation. Vii

- 291 4. Kritikos A, Manuel O. Bloodstream infections after solid-organ transplantation. Virulence.<br>292 2016;7(3):329-40. <sup>292</sup>2016;7(3):329-40.
- 293 5. Candel FJ, Grima E, Matesanz M, Cervera C, Soto G, Almela M, et al. Bacteremia and<br>294 Septic shock after solid-organ transplantation. Transplant Proc. 2005:37(9):4097-9. 294 septic shock after solid-organ transplantation. Transplant Proc. 2005;37(9):4097-9.<br>295 6. Moreno A. Cervera C. Gavalda J. Rovira M. de la Camara R. Jarque I. et al.
- 295 6. Moreno A, Cervera C, Gavalda J, Rovira M, de la Camara R, Jarque I, et al. Bloodstream<br>296 infections among transplant recipients: results of a nationwide surveillance in Spain. Am J 296 infections among transplant recipients: results of a nationwide surveillance in Spain. Am J<br>297 Transplant. 2007:7(11):2579-86.
- 297 Transplant. 2007;7(11):2579-86.<br>298 7. Adelman MW, Connor AA 298 7. Adelman MW, Connor AA, Hsu E, Saharia A, Mobley CM, Victor DW, III, et al. Bloodstream<br>299 infections after solid organ transplantation: clinical epidemiology and antimicrobial resistance 299 infections after solid organ transplantation: clinical epidemiology and antimicrobial resistance<br>300 (2016–21), JAC-Antimicrobial Resistance, 2024:6(1),
- <sup>300</sup>(2016–21). JAC-Antimicrobial Resistance. 2024;6(1). 301 8. Anesi JA, Lautenbach E, Tamma PD, Thom KA, Blumberg EA, Alby K, et al. Risk Factors for 302<br>302 Extended-Spectrum beta-lactamase-Producing Enterobacterales Bloodstream Infection Among 302 Extended-Spectrum beta-lactamase-Producing Enterobacterales Bloodstream Infection Among<br>303 Solid-Organ Transplant Recipients. Clin Infect Dis. 2021;72(6):953-60.
- 303 Solid-Organ Transplant Recipients. Clin Infect Dis. 2021;72(6):953-60.<br>304 9. Kadri SS, Lai YLE, Ricotta EE, Strich JR, Babiker A, Rhee C, et 304 9. Kadri SS, Lai YLE, Ricotta EE, Strich JR, Babiker A, Rhee C, et al. External Validation of<br>305 Difficult-to-Treat Resistance Prevalence and Mortality Risk in Gram-Negative Bloodstream Infect 305 Difficult-to-Treat Resistance Prevalence and Mortality Risk in Gram-Negative Bloodstream Infection<br>306 Using Electronic Health Record Data From 140 US Hospitals. Open Forum Infect Dis. 306 Using Electronic Health Record Data From 140 US Hospitals. Open Forum Infect Dis.<br>307 2019;6(4):ofz110.
- 307 2019;6(4):ofz110.<br>308 10. Anesi JA. l 308 10. Anesi JA, Lautenbach E, Thom KA, Tamma PD, Blumberg EA, Alby K, et al. Clinical<br>309 Outcomes and Risk Factors for Carbapenem-resistant Enterobacterales Bloodstream Infect 309 Outcomes and Risk Factors for Carbapenem-resistant Enterobacterales Bloodstream Infection in<br>310 Solid Organ Transplant Recipients. Transplantation. 2023;107(1):254-63. 310 Solid Organ Transplant Recipients. Transplantation. 2023;107(1):254-63.<br>311 11. van Delden C. Stampf S. Hirsch HH. Manuel O. Meylan P. Cusini.
- 311 11. van Delden C, Stampf S, Hirsch HH, Manuel O, Meylan P, Cusini A, et al. Burden and<br>312 Timeline of Infectious Diseases in the First Year After Solid Organ Transplantation in the Swis 312 Timeline of Infectious Diseases in the First Year After Solid Organ Transplantation in the Swiss<br>313 Transplant Cohort Study. Clin Infect Dis. 2020:71(7):e159-e69. 313 Transplant Cohort Study. Clin Infect Dis. 2020;71(7):e159-e69.<br>314 12. Ye QF. Zhao J. Wan QQ. Qiao BB. Zhou JD. Frequencv
- 314 12. Ye QF, Zhao J, Wan QQ, Qiao BB, Zhou JD. Frequency and clinical outcomes of ESKAPE<br>315 bacteremia in solid organ transplantation and the risk factors for mortality. Transpl Infect Dis. 315 bacteremia in solid organ transplantation and the risk factors for mortality. Transpl Infect Dis.<br>316 2014:16(5):767-74.
- <sup>316</sup>2014;16(5):767-74. 317 – 13. – Neofytos D, Stampf S, Hoessly LD, D'Asaro M, Tang GN, Boggian K, et al. Bacteremia<br>318 – During the First Year After Solid Organ Transplantation: An Epidemiological Update. Open Foru 318 During the First Year After Solid Organ Transplantation: An Epidemiological Update. Open Forum<br>319 Infect Dis. 2023;10(6):ofad247.
- 319 Infect Dis. 2023;10(6):ofad247.<br>320 14. Parker MT, Organizatior 320 14. Parker MT, Organization WH. Hospital-acquired infections: guidelines to laboratory methods:<br>321 World Health Organization. Regional Office for Europe; 1978.
- 321 World Health Organization. Regional Office for Europe; 1978.<br>322 15. WHO. WHO Bacterial Priority Pathogens List, 2024: ba 322 15. WHO. WHO Bacterial Priority Pathogens List, 2024: bacterial pathogens of public health<br>323 importance to guide research, development and strategies to prevent and control antimicrobial 323 importance to guide research, development and strategies to prevent and control antimicrobial<br>324 Fresistance. Geneva: 2024. 324 resistance. Geneva; 2024.<br>325 16. Page MJ, McKenzie
- 325 16. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The<br>326 PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Bmj. 326 PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Bmj.<br>327 2021;372:n71.
- 327 2021;372:n71.<br>328 17. Wells G
- 328 17. Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M. The Newcastle-Ottawa<br>329 Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses [Available fr 329 Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses [Available from:<br>330 http://www.ohri.ca/programs/clinical epidemiology/oxford.htm. 330 http://www.ohri.ca/programs/clinical\_epidemiology/oxford.htm.<br>331 18. Gagliotti C. Morsillo F. Moro ML. Masiero L. Procaccio
- 331 18. Gagliotti C, Morsillo F, Moro ML, Masiero L, Procaccio F, Vespasiano F, et al. Infections in<br>332 liver and lung transplant recipients: a national prospective cohort. Eur J Clin Microbiol Infect Dis.
- 332 liver and lung transplant recipients: a national prospective cohort. Eur J Clin Microbiol Infect Dis.<br>333 2018;37(3):399-407. <sup>333</sup>2018;37(3):399-407.
- 334 19. Karruli A, de Cristofaro J, Andini R, Iossa D, Bernardo M, Amarelli C, et al. Risk Factors and<br>335 Outcome of Multidrug-Resistant Infections after Heart Transplant: A Contemporary Single Center
- 335 Outcome of Multidrug-Resistant Infections after Heart Transplant: A Contemporary Single Center<br>336 Experience. Microorganisms. 2021:9(6). Experience. Microorganisms. 2021;9(6).

337 20. Dubler S, Lenz M, Zimmermann S, Richter DC, Weiss KH, Mehrabi A, et al. Does<br>338 vancomycin resistance increase mortality in Enterococcus faecium bacteraemia after orth 338 vancomycin resistance increase mortality in Enterococcus faecium bacteraemia after orthotopic liver<br>339 transplantation? A retrospective study. Antimicrob Resist Infect Control. 2020;9(1):22. 339 transplantation? A retrospective study. Antimicrob Resist Infect Control. 2020;9(1):22.<br>340 21. Mouloudi E, Massa E, Papadopoulos S, Iosifidis E, Roilides I, Theodoridou T, 340 21. Mouloudi E, Massa E, Papadopoulos S, Iosifidis E, Roilides I, Theodoridou T, et al.<br>341 Bloodstream infections caused by carbapenemase-producing Klebsiella pneumoniae amor 341 Bloodstream infections caused by carbapenemase-producing Klebsiella pneumoniae among<br>342 bintensive care unit patients after orthotopic liver transplantation: risk factors for infection and i 342 intensive care unit patients after orthotopic liver transplantation: risk factors for infection and impact<br>343 of resistance on outcomes. Transplant Proc. 2014;46(9):3216-8. 343 of resistance on outcomes. Transplant Proc. 2014;46(9):3216-8.<br>344 22. Min EK, Yim SH, Choi MC, Lee JG, Joo DJ, Kim MS, et a 344 22. Min EK, Yim SH, Choi MC, Lee JG, Joo DJ, Kim MS, et al. Incidence, mortality, and risk<br>345 factors associated with carbapenem-resistant Acinetobacter baumannii bacteremia within 30 da 345 factors associated with carbapenem-resistant Acinetobacter baumannii bacteremia within 30 days<br>346 Fafter liver transplantation. Clin Transplant. 2023;37(5):e14956. 346 after liver transplantation. Clin Transplant. 2023;37(5):e14956.<br>347 23. Yang W, Ding L, Han R, Yin D, Wu S, Yang Y, et al. Cur 347 23. Yang W, Ding L, Han R, Yin D, Wu S, Yang Y, et al. Current status and trends of<br>348 antimicrobial resistance among clinical isolates in China: a retrospective study of CHINE 348 antimicrobial resistance among clinical isolates in China: a retrospective study of CHINET from<br>349 2018 to 2022. One Health Advances. 2023:1(1):8. 349 2018 to 2022. One Health Advances. 2023;1(1):8.<br>350 24. Kim D, Yoon EJ, Hong JS, Choi MH, Kim F 350 24. Kim D, Yoon EJ, Hong JS, Choi MH, Kim HS, Kim YR, et al. Major Bloodstream Infection-<br>351 Causing Bacterial Pathogens and Their Antimicrobial Resistance in South Korea, 2017-2019: Pha 351 Causing Bacterial Pathogens and Their Antimicrobial Resistance in South Korea, 2017-2019: Phase<br>352 I Report From Kor-GLASS. Front Microbiol. 2021;12:799084. 352 I Report From Kor-GLASS. Front Microbiol. 2021;12:799084.<br>353 25. Kim SI. Bacterial infection after liver transplantation. W 353 25. Kim SI. Bacterial infection after liver transplantation. World J Gastroenterol.<br>354 2014;20(20):6211-20. 354 2014;20(20):6211-20.<br>355 26. Kim SH. Mun 3 355 26. Kim SH, Mun SJ, Ko JH, Huh K, Cho SY, Kang CI, et al. Poor outcomes of early recurrent<br>356 post-transplant bloodstream infection in living-donor liver transplant recipients. Eur J Clin Microbio 356 post-transplant bloodstream infection in living-donor liver transplant recipients. Eur J Clin Microbiol<br>357 hfect Dis. 2021:40(4):771-8. <sup>357</sup>Infect Dis. 2021;40(4):771-8. 358 27. Kim YJ, Kim SI, Wie SH, Kim YR, Hur JA, Choi JY, et al. Infectious complications in living-<br>359 donor liver transplant recipients: a 9-vear single-center experience. Transpl Infect Dis. 359 donor liver transplant recipients: a 9-year single-center experience. Transpl Infect Dis.<br>360 2008;10(5):316-24. 360 2008;10(5):316-24.<br>361 28. Qiao M. Yino 361 28. Qiao M, Ying GG, Singer AC, Zhu YG. Review of antibiotic resistance in China and its 362 environment. Environ Int. 2018;110:160-72. 362 environment. Environ Int. 2018;110:160-72.<br>363 29. Jean SS, Hsueh PR. High burden of 363 29. Jean SS, Hsueh PR. High burden of antimicrobial resistance in Asia. Int J Antimicrob Agents.<br>364 2011;37(4):291-5. 364 2011;37(4):291-5.<br>365 30. CDC. Antil 365 30. CDC. Antibiotic Resistance Threats in the United States, 2019. Atlanta, GA: U.S. Department<br>366 of Health and Human Services, CDC: 2019. 366 of Health and Human Services, CDC; 2019.<br>367 31. Werner G. Coque TM. Hammerum A 367 31. Werner G, Coque TM, Hammerum AM, Hope R, Hryniewicz W, Johnson A, et al. Emergence<br>368 and spread of vancomvcin resistance among enterococci in Europe. Eurosurveillance. 368 and spread of vancomycin resistance among enterococci in Europe. Eurosurveillance.<br>369 2008;13(47):19046. 369 2008;13(47):19046.<br>370 32. Ma J, Song 〉 370 32. Ma J, Song X, Li M, Yu Z, Cheng W, Yu Z, et al. Global spread of carbapenem-resistant<br>371 Enterobacteriaceae: Epidemiological features, resistance mechanisms, detection and therapy. 371 Enterobacteriaceae: Epidemiological features, resistance mechanisms, detection and therapy.<br>372 Microbiol Res. 2023;266:127249. 372 Microbiol Res. 2023;266:127249.<br>373 33. Coque TM. Baquero F. Ca 373 33. Coque TM, Baquero F, Canton R. Increasing prevalence of ESBL-producing<br>374 Enterobacteriaceae in Europe. Euro Surveill. 2008:13(47):19044. 374 Enterobacteriaceae in Europe. Euro Surveill. 2008;13(47):19044.<br>375 34. Proportion of bloodstream infection due to methicillin-resis 375 34. Proportion of bloodstream infection due to methicillin-resistant Staphylococcus aureus<br>376 (MRSA) (%) [Internet]. WHO. 2024. Available from: https://data.who.int/indicators/i/5dd9606. 376 (MRSA) (%) [Internet]. WHO. 2024. Available from: <u>https://data.who.int/indicators/i/5dd9606</u>.<br>377 35. Bezabih YM, Bezabih A, Dion M, Batard E, Teka S, Obole A, et al. Comparison of the 377 35. Bezabih YM, Bezabih A, Dion M, Batard E, Teka S, Obole A, et al. Comparison of the global<br>378 prevalence and trend of human intestinal carriage of ESBL-producing Escherichia coli between 378 prevalence and trend of human intestinal carriage of ESBL-producing Escherichia coli between<br>379 healthcare and community settings: a systematic review and meta-analysis. JAC Antimicrob Re 379 healthcare and community settings: a systematic review and meta-analysis. JAC Antimicrob Resist.<br>380 2022:4(3):dlac048. 380 2022;4(3):dlac048.<br>381 36. Diekema D. 381 36. Diekema DJ, Pfaller MA, Shortridge D, Zervos M, Jones RN. Twenty-Year Trends in<br>382 Antimicrobial Susceptibilities Among Staphylococcus aureus From the SENTRY Antimicrobi 382 Antimicrobial Susceptibilities Among Staphylococcus aureus From the SENTRY Antimicrobial<br>383 Surveillance Program. Open Forum Infect Dis. 2019;6(Suppl 1):S47-s53. 383 Surveillance Program. Open Forum Infect Dis. 2019;6(Suppl 1):S47-s53.<br>384 37. Smibert O, Satlin MJ, Nellore A, Peleg AY. Carbapenem-Resistant 384 37. Smibert O, Satlin MJ, Nellore A, Peleg AY. Carbapenem-Resistant Enterobacteriaceae in 385 Solid Organ Transplantation: Management Principles. Curr Infect Dis Rep. 2019;21(7):26. 385 Solid Organ Transplantation: Management Principles. Curr Infect Dis Rep. 2019;21(7):26.<br>386 S8. Sellore A. Huprikar S. Practice AICo. Vancomycin-resistant Enterococcus in solid c 386 38. Nellore A, Huprikar S, Practice AICo. Vancomycin-resistant Enterococcus in solid organ<br>387 transplant recipients: Guidelines from the American Society of Transplantation Infectious Diseas 387 transplant recipients: Guidelines from the American Society of Transplantation Infectious Diseases<br>388 Community of Practice. Clin Transplant. 2019;33(9):e13549. 388 Community of Practice. Clin Transplant. 2019;33(9):e13549.<br>389 39. WHO. Antimicrobial resistance: global report on surve 389 39. MHO. Antimicrobial resistance: global report on surveillance. Geneva: WHO; 2014.<br>390 40. Jiang Y, Ding Y, Wei Y, Jian C, Liu J, Zeng Z. Carbapenem-resistant Acinetobacter 390 40. Jiang Y, Ding Y, Wei Y, Jian C, Liu J, Zeng Z. Carbapenem-resistant Acinetobacter<br>391 baumannii: A challenge in the intensive care unit. Front Microbiol. 2022:13:1045206. baumannii: A challenge in the intensive care unit. Front Microbiol. 2022;13:1045206.

392 41. Doughty EL, Liu H, Moran RA, Hua X, Ba X, Guo F, et al. Endemicity and diversification of<br>393 carbapenem-resistant Acinetobacter baumannii in an intensive care unit. Lancet Reg Health West 393 carbapenem-resistant Acinetobacter baumannii in an intensive care unit. Lancet Reg Health West<br>394 Pac. 2023:37:100780. <sup>394</sup>Pac. 2023;37:100780.

395 42. Donnelly JP, Locke JE, MacLennan PA, McGwin G, Jr., Mannon RB, Safford MM, et al.<br>396 Inpatient Mortality Among Solid Organ Transplant Recipients Hospitalized for Sepsis and Seve

396 Inpatient Mortality Among Solid Organ Transplant Recipients Hospitalized for Sepsis and Severe<br>397 Sepsis. Clin Infect Dis. 2016:63(2):186-94. 397 Sepsis. Clin Infect Dis. 2016;63(2):186-94.<br>398 43. Kalil AC. Sved A. Rupp ME. Chamb

398 43. Kalil AC, Syed A, Rupp ME, Chambers H, Vargas L, Maskin A, et al. Is bacteremic sepsis<br>399 associated with higher mortality in transplant recipients than in nontransplant patients? A matchec 399 associated with higher mortality in transplant recipients than in nontransplant patients? A matched<br>400 case-control propensity-adjusted study. Clin Infect Dis. 2015:60(2):216-22. 400 case-control propensity-adjusted study. Clin Infect Dis. 2015;60(2):216-22.<br>401 44. Bodro M, Sabe N, Tubau F, Llado L, Baliellas C, Roca J, et al. Risk

- 401 44. Bodro M, Sabe N, Tubau F, Llado L, Baliellas C, Roca J, et al. Risk factors and outcomes of 402 bacteremia caused by drug-resistant ESKAPE pathogens in solid-organ transplant recipients. 402 bacteremia caused by drug-resistant ESKAPE pathogens in solid-organ transplant recipients.<br>403 Transplantation. 2013:96(9):843-9.
- 403 Transplantation. 2013;96(9):843-9.<br>404 45. Ye QF, Zhou W, Wan QQ. D 404 45. Ye QF, Zhou W, Wan QQ. Donor-derived infections among Chinese donation after cardiac<br>405 death liver recipients. World J Gastroenterol. 2017;23(31):5809-16.
- 405 death liver recipients. World J Gastroenterol. 2017;23(31):5809-16.<br>406 46. Eichenberger EM, Ruffin F, Sharma-Kuinkel B, Dagher M, P 406 46. Eichenberger EM, Ruffin F, Sharma-Kuinkel B, Dagher M, Park L, Kohler C, et al. Bacterial<br>407 genotype and clinical outcomes in solid organ transplant recipients with Staphylococcus aureus 407 genotype and clinical outcomes in solid organ transplant recipients with Staphylococcus aureus<br>408 Dacteremia. Transpl Infect Dis. 2021;23(6):e13730.
- 408 bacteremia. Transpl Infect Dis. 2021;23(6):e13730.<br>409 47. Linares L. Garcia-Goez JF. Cervera C. Alme
- <sup>409</sup>47. Linares L, Garcia-Goez JF, Cervera C, Almela M, Sanclemente G, Cofan F, et al. Early
- 410 bacteremia after solid organ transplantation. Transplant Proc. 2009;41(6):2262-4.<br>411 48. Pezzani MD, Arieti F, Rajendran NB, Barana B, Cappelli E, De Rui ME, et
- 411 48. Pezzani MD, Arieti F, Rajendran NB, Barana B, Cappelli E, De Rui ME, et al. Frequency of<br>412 bloodstream infections caused by six key antibiotic-resistant pathogens for prioritization of researcl
- 412 bloodstream infections caused by six key antibiotic-resistant pathogens for prioritization of research<br>413 and discovery of new therapies in Europe: a systematic review. Clin Microbiol Infect. 2024;30 Suppl 413 and discovery of new therapies in Europe: a systematic review. Clin Microbiol Infect. 2024;30 Suppl<br>414 1:S4-S13.
- 1:S4-S13.

### <sup>416</sup>**Fig. 1: PRISMA flow diagram**







Abbreviations: 3GCR-E – Third-generation cephalosporin-resistant Enterobacterales; CRAB – carbapenem-resistant *Acinetobacter baumannii*; CRE – carbapenem-resistant Enterobacterales; CRP – carbapenem-resistant *Pseudomonas aeruginosa;* MRSA –methicillin-resistant *Staphylococcus aureus*; VRE – vancomycin-resistant *Enterococcus*.

							<b>North</b>	<b>South</b>	
	<b>Pooled</b>	$2002 - 2010$	$2011 - 2015$	$2016 - 2020$	$2021 - 2024$	<b>Europe</b>	America	America	Asia
	$(n = 49)$	$(n = 10)$	$(n = 15)$	$(n = 12)$	$(n = 12)$	$(n = 16)$	$(n = 12)$	$(n = 4)$	$(n = 17)$
3GCR-E, median (IQR)	38.2%	42.3%	30.0%	33.8%	40.0%	29.3%	33.5%	43.4%	63.1%
(% of Enterobacterales)	$(27 - 49%)$	$(33.6 - 50.9\%)$	$(27.6 - 56.5%)$	$(20.8 - 40.8\%)$	$(35.0 - 47.5%)$	$(21.2 - 40.5%)$	$(30.4 - 36.2%)$	$(41.9 - 44.9\%)$	$(45.2 - 72.9%)$
CRE, median (IQR)	13.6%			28.6%	6.3%		12.9%		35.7%
(% of Enterobacterales)	$(8.7 - 37.0\%)$	$9.5\%$ *	45.5%*	$(14.3 - 61.9\%)$	$(3.6 - 9.1\%)$	14.3%*	$(7.8 - 13.6%)$	NR.	$(8.3 - 63.1\%)$
CRAB, median (IQR)	59.2%	60.0%*	54.2%	72.4%	84.6%*	50.0%	<b>NR</b>	53.6%	60.0%
(% of A. baumannii)	$(50.0 - 77.4%)$		$(48.2 - 73.3%)$	$(6.2 - 83.6%)$		$(50.0 - 61.4%)$		$(42.9 - 64.3%)$	$(54.2 - 88.7%)$
CRPA, median (IQR)	33.3%		33.3%	32.4%	17.0%	45.2%	38.9%		27.5%
(% of P. aeruginosa)	$(24.3 - 43.8\%)$	<b>NR</b>	$(33.3 - 74.3%)$	$(27.9 - 36.8\%)$	$(6.8 - 29.9\%)$	$(25.0 - 61.4%)$	$(36.1 - 41.7%)$	$87.5*$	$(21.0 - 32.8%)$
MRSA, median (IQR)	50.4%	77.8%	56.0%	77.9%	31.5%	31.7%	50.5%	64.3%	86.2%
(% of S. aureus)	$(36.4 - 86.7%)$	$(47.40 - 100\%)$	$(35.5 - 84.3%)$	$(73.9 - 81.8\%)$	$(15.6 - 47.4%)$	$(22.0 - 46.6%)$	$(38.1 - 77.8%)$	$(53.6 - 75.0\%)$	$(77.3 - 94.6%)$
VRE, median (IQR)	38.1%	55.6%	15.0%	53.0%	36.9%	3.0%	76.6%		32.3%
% of E. faecium)	$(3.0 - 67.6%)$	$(27.88 - 77.8%)$	$(0.0 - 36.1\%)$	$(28.4 - 76.0\%)$	$(8.9 - 62.2\%)$	$(0.0 - 23.5%)$	$(57.2 - 89.4\%)$	38.6%*	$(6.6 - 51.2%)$

**Table 1: Proportions of bloodstream infections caused by resistant organisms in solid-organ transplant recipients by time period and region** 

\*only single studies available, unable to calculate IQR. NR = not reported.

Abbreviations: 3GCR-E – Third-generation cephalosporin-resistant Enterobacterales; CRAB – carbapenem-resistant *Acinetobacter baumannii*; CRE – carbapenem-resistant Enterobacterales; CRP – carbapenem-resistant *Pseudomonas aeruginosa;* MRSA –methicillin-resistant *Staphylococcus aureus*; VRE – vancomycin-resistant *Enterococcus*.



**Table 2: Mortality due to bloodstream infection from multidrug resistant organism/s in solid organ transplant recipients:** 





Abbreviations: 3GCR-E – Third-generation cephalosporin-resistant Enterobacterales, BSI – bloodstream infection, CRAB – carbapenem-resistant *Acinetobacter baumannii*, CRE – carbapenem-resistant Enterobacterales, CRKP – carbapenem-resistant *Klebsiella pneumoniae*, CRPA – carbapenemresistant *Pseudomonas aeruginosa*, MDRO – multi-drug resistant organism/s, MRSA – methicillin-resistant *Staphylococcus aureus*, SOT – solid organ transplant, VRE – vancomycin-resistant *Enterococcus faecium*.